Thymosin Beta-4

Thymosin Beta-4 (Tβ4) is a 43-amino acid peptide found in virtually all nucleated mammalian cells and in plasma and wound fluid. Its most studied biochemical function is as the principal G-actin sequestering molecule in eukaryotic cells. By binding monomeric (globular) actin, Tβ4 prevents its polymerization into filamentous actin, regulating cytoskeletal dynamics that govern cell migration, wound contraction, and new vessel formation.

The peptide contains structurally distinct functional domains. Research has characterized these regions as follows:

• Amino acids 1–4 (N-terminal tetrapeptide Ac-SDKP): anti-inflammatory and anti-fibrotic activity, independent of actin binding • Amino acids 1–15: anti-apoptotic effects mediated through Bcl-2 upregulation and caspase suppression • Amino acids 17–23: angiogenic domain, promotes VEGF expression and endothelial cell migration

Separately from actin sequestration, Tβ4 suppresses NF-κB by directly targeting the RelA/p65 subunit and blocking nuclear translocation, reducing downstream transcription of TNF-α, IL-1β, and IL-8. In vitro studies using human corneal epithelial cells demonstrated this anti-inflammatory action is independent of actin-binding capacity. Tβ4 additionally modulates extracellular matrix remodeling by upregulating laminin-332, fibronectin, and matrix metalloproteases, and supports recruitment of stem and progenitor cells to sites of injury.

The strongest human evidence concerns dermal wound healing. A Phase II trial enrolling 143 patients with chronic pressure ulcers and venous stasis ulcers reported that topical Tβ4 accelerated wound closure by approximately one month compared to placebo in patients who achieved complete healing. A separate European double-blind, dose-escalation trial randomized 73 patients with venous stasis ulcers across ten sites; preliminary data suggested roughly 25% of patients with small to moderate wounds achieved complete closure within an 84-day treatment window. A Phase II trial for epidermolysis bullosa (NCT00311766) was registered but terminated early due to insufficient patient enrollment and drug expiration before efficacy could be assessed.

A first-in-human Phase I study published in 2021 (PMID 34346165) enrolled 54 healthy Chinese volunteers for single-dose ascending intravenous administration (0.05–25.0 μg/kg) and 30 volunteers for multiple-dose administration (0.5–5.0 μg/kg daily for 10 days). No dose-limiting toxicities or serious adverse events were reported; pharmacokinetics were dose-proportional with no accumulation. This Phase I work supported advancement to an efficacy study in acute myocardial infarction (NCT05984134), currently registered on ClinicalTrials.gov.

A Phase II randomized trial of Tβ4 ophthalmic solution in dry eye patients (NCT01387347) demonstrated a 35.1% reduction in ocular discomfort and a 59.1% decrease in corneal fluorescein staining versus controls.

In animal models, topical or systemic Tβ4 increased reepithelialization in rat full-thickness wounds by 42% at day 4 and up to 61% at day 7 relative to saline controls (PMID 10469335), with accompanying increases in collagen deposition and blood vessel formation. No large-scale randomized controlled trials for musculoskeletal pain or soft-tissue injury — the primary driver of community use — have been completed in humans as of mid-2026.

Typical dosage: 2-10 mg (weekly).

No FDA-approved dosing guidelines exist for Tβ4 in any indication. The following summarizes doses used in research contexts and reported in community or compounding clinic practice.

In Phase II wound-healing trials, Tβ4 was administered as a topical gel at concentrations of 0.01%, 0.03%, or 0.1%, applied daily for up to 84 days. In the Phase I intravenous safety study, single doses ranged from 0.05 to 25.0 μg/kg, and multiple doses of 0.5, 2.0, and 5.0 μg/kg were given daily for 10 days.

For subcutaneous or intramuscular injection — the route most commonly described in off-label compounding clinic and community settings — no peer-reviewed dose-ranging studies in humans exist. Protocols reported from compounding clinics typically describe a loading phase of 2.0–5.0 mg administered subcutaneously 2–3 times per week for 4–6 weeks, followed by a maintenance phase of 2.0–4.0 mg every 1–2 weeks. These figures are not validated by controlled trials and originate from practitioner experience and athlete-community reports. TB-500, a synthetic peptide sold as a research chemical analog of Tβ4, is the form most often encountered outside of clinical settings.

This information is provided for educational purposes only and does not constitute medical advice. Tβ4 and TB-500 are not FDA-approved drug products; use outside of supervised research or clinical settings involves unknown risks and should not be undertaken without evaluation by a licensed clinician.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The most widely discussed combination in athletic-recovery and compounding clinic practice pairs Tβ4 or TB-500 with BPC-157 (Body Protection Compound-157). The stated rationale invokes complementary mechanisms: BPC-157 is proposed to act on growth hormone receptors and nitric oxide pathways to accelerate tendon, ligament, and gastrointestinal repair, while Tβ4 contributes actin-regulatory, anti-inflammatory, and angiogenic activity. A 2021 retrospective case series by Lee and Padgett compared knee injections of BPC-157 alone to a combination with Thymosin Beta-4, but this is low-quality observational data, not a controlled trial. All clinical use of this combination must be considered anecdotal.

Preclinical research has explored Tβ4 co-administration with mesenchymal stem cells to improve engraftment under hypoxic conditions, and with endothelial progenitor cells to enhance post-infarction angiogenesis. These are animal-model findings only and have not been evaluated in controlled human trials.

Thymosin Beta-4 is not currently FDA-approved for any indication. Effective April 22, 2026, the FDA removed Thymosin Beta-4 from Category 2 of its Section 503A bulk drug substances list after the original nominators withdrew their nominations. This removal lifts the prior “significant safety risk” designation but does not place Thymosin Beta-4 on the 503A Bulks List. Compounding pharmacies may prepare it with a valid physician prescription and pharmaceutical-grade API from an FDA-registered manufacturer. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review this substance at its July 23–24, 2026 public meeting. Removed from FDA Category 2 effective April 22, 2026. Selected for PCAC review Day 1 — July 23, 2026. PCAC agenda: BPC-157, KPV, TB-500, MOTS-c. NOT currently on 503A Bulks List — requires physician Rx. Source: FDA Advisory Committee Calendar / Lengea Law, May 2026.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Well-tolerated

In completed Phase I and Phase II human trials, Tβ4 has been consistently reported as safe and well tolerated. The intravenous Phase I study — reaching single doses of 25.0 μg/kg — recorded only mild to moderate adverse events with no dose-limiting toxicities and no serious adverse events across 84 total healthy volunteers. Wound-healing topical trials similarly noted no significant systemic reactions.

In community reports of subcutaneous injection (TB-500), the most frequently cited adverse effects are transient injection-site reactions — redness, swelling, or discomfort — and occasional mild headache or fatigue. These are anecdotal and not systematically documented in controlled studies.

A theoretical safety concern arises from in vitro and ex vivo data showing that Tβ4 overexpression is associated with increased malignant behavior and metastatic capacity in certain solid tumor cell lines, including non-small cell lung cancer. This effect likely relates to its angiogenic and cell-migratory activities. No human clinical trial has characterized this as an observed clinical risk, but use in individuals with active or uncontrolled malignancy represents a plausible theoretical contraindication. Effects appear cancer-type dependent: some hematologic malignancies show inverse associations with Tβ4 expression.

Tβ4 and TB-500 are listed as prohibited substances under Section S2 (Growth Factors and Growth Factor Modulators) on the World Anti-Doping Agency (WADA) Prohibited List, a classification in place since 2018. Long-term safety data for the subcutaneous doses and frequencies used in community practice are not available, and compounding preparations are not subject to FDA pharmaceutical manufacturing standards.